 Orgenesis Inc NASDAQ:ORGS FRA:45O announced Thursday that it has entered the second phase of its collaboration with Hospital Infantil Universitario Niño Jesús in Madrid, Spain, focused on the hospitals proprietary solid tumor treatment, Celyvir. The collaboration is focused on an exclusive license agreement to further develop and commercialize Celyvir. 